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Abstract
Background: To compare the distribution of the intrinsic molecular subtypes of breast cancer based on
immunohistochemical profile in the five major geographic regions of Brazil, a country of continental
dimension, with a wide racial variation of people.
Methods: The study was retrospective observational. We classified 5,687 invasive breast cancers by molecular
subtype based on immunohistochemical expression of estrogen-receptor (ER), progesterone-receptor (PR), human
epidermal growth factor receptor 2 (HER2), and Ki-67 proliferation index. Cases were classified as luminal A (ER and/or
PR positive and HER2 negative, Ki-67 < 14%), luminal B (ER and/or PR positive, HER2 negative, and Ki-67 > 14%),
triple-positive (ER and/or PR positive and HER2 positive), HER2-enriched (ER and PR negative, and HER2- positive),
and triple-negative (TN) (ER negative, PR negative, and HER2- negative). Comparisons of the ages of patients and
molecular subtypes between different geographic regions were performed.
Results: South and Southeast regions with a higher percentage of European ancestry and higher socioeconomic
status presented with the highest proportion of luminal tumors. The North region presented with more aggressive
subtypes (HER2-enriched and triple-negative), while the Central-West region predominated triple-positive carcinomas.
The Northeast—a region with a high African influence—presented intermediate frequency of the different molecular
subtypes. The differences persisted in subgroups of patients under and over 50 years.
Conclusions: The geographic regions differ according to the distribution of molecular subtypes of breast cancer.
However, other differences, beside those related to African ancestry, such as socioeconomic, climatic, nutritional,
and geographic, have to be considered to explain our results. The knowledge of the differences in breast cancer
characteristics among the geographic regions may help to organize healthcare programs in large countries like
Brazil with diverse economic and race composition among different geographic regions.
Keywords: Breast cancer, Epidemiology, Brazilian races, Intrinsic molecular subtypes
Background
Breast cancer remains a major health problem responsible
for 458,400 deaths worldwide in 2008 [1]. The molecular
intrinsic subtypes discovered in 1999 provided additional
information on the clinical outcome independent of con-
ventional prognosticators such as tumor size, tumor grade
and lymph node status [2]. More importantly, various
molecular subtypes respond differently to various chemo-
therapy treatments, so an accurate subclassification is im-
portant for deciding treatment options [3-6].
Racial/ethnic differences have been observed among
the different molecular subtypes [7-12] with the most
documented being the relatively high incidence of basal
type breast cancer (also called “triple negative”) among
African-American women compared to Caucasian fe-
males [7,8,12,13]. Although non-white women, particu-
larly of African descent, have a lower incidence of breast
cancer, this particular race group present with more ag-
gressive tumors and a higher mortality rate [13,14].
We investigated whether a similar effect of race could
be present in Brazil, a country of a continental size with
a wide variation in the distribution of people from vari-
ous racial backgrounds in its five major geographic re-
gions. Brazil is a large country with the fifth largest area
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and the fifth largest population in the world with a total
of more than 190 million inhabitants according to the
2010 official census [15]. It has 26 states divided over five
major geographic regions: North, Northeast, Central-West,
Southeast and South. The social-economic situation and
ethnic backgrounds vary greatly among these regions
and include descendants from Amerindians, European
immigrants, Asians, and Africans brought to the con-
tinent as slaves in the 18th century. Although there is a
tendency of one race predominant over another in
these regions (for example, Amerindians in the North,
blacks in the Northeast and Europeans in the South
and Southeast), there are some ethnic variations in the
Brazilian population mainly due to a high rate of inter-
racial marriage. Anti-miscegenation and segregation laws
have not been part of the Brazilian culture, so Brazil is a
home to a population characterized by a color continuum
between white and black races. This leads to a well-known
difficulty in categorizing races because they lack a precise
legal definition [16].
Previous studies actually demonstrated that in Brazil
color, as determined by a physical evaluation, is a poor
predictor of genetic ancestry estimated by molecular
markers [17,18]. There remain, however, significant
geographical differences in the racial makeup of the
population, influenced by diverse geographic and economic
characteristics of this country with the size comparable to
a continent. The knowledge of possible differences in a
large and ethnically complex country such as Brazil clearly
would benefit not only the study of breast cancer in this
country, but also the comprehension of the mechanisms
involved in different molecular subtypes, not to mention
the opportunity to develop more efficient strategies of
prevention and early detection of breast cancer, particu-
larly among the minorities.
In Brazil, federal law regulates mammographic screening
and it has been offered to all women over 50 years of age
since 2009. The number of new cases of breast cancer in
Brazil estimated in 2014 was 57,120 [19]. Currently, there is
no data regarding the distribution of breast cancer molecu-
lar subtypes in Brazil or even within individual states of this
country. Our aim is to compare the distribution of the in-
trinsic molecular subtypes by the immunohistochemical
surrogates in the five major geographic regions in Brazil.
Methods
Patient selection
All patient data were obtained from the files of Consultoria
em Patologia, a private surgical pathology laboratory lo-
cated in the city of Botucatu, State of São Paulo, Brazil.
Consultoria em Patologia is a reference laboratory and ana-
lyzes over 5,000 breast cancer cases per year. These cases
usually are sent by pathologists and oncologists from all
five geographic regions of Brazil in order to be evaluated
for predictive and prognostic immunohistochemical
markers, i.e., estrogen and progesterone receptors (ER
and PR), human epidermal growth factor receptor 2
(HER2) and Ki-67 proliferation index. Age at diagnosis
and the state of origin of the patients were obtained
from the pathological report. Geographic regions of
Brazil were classified as North, Northeast, Central-West,
South, and Southeast. We selected consecutive cases of
invasive breast cancer from July 2009 to March 2011
with assessable immunohistochemical study of ER, PR,
HER2 and Ki-67. One of the reasons this period of time
was chosen is that all these cases had the immunohisto-
chemistry study performed using exactly the same
immunohistochemical protocol. Another reason was
that we included only the cases sent for routine prog-
nostic and predictive factors determination. We excluded
in situ and microinvasive carcinomas as well the cases,
which were sent for second opinion.
Immunohistochemistry analysis
ER, PR, and HER2 status and Ki-67 proliferation index
were determined at the time of the patient’s cancer
assessment by an immunohistochemical method on a
selected tumor block. ER and PR were considered
positive with >1% of the nuclear staining in tumor
cells, although in all cases except in three, ER and PR
results showed > 10% of positive cells. HER2 was con-
sidered positive with a 3+ score and negative with a 0+ or
1+ immunoreactivity using the previous ASCO/CAP rec-
ommendation [20]. Also, based on ASCO/CAP recom-
mendations, breast cancers with 2+ immunohistochemical
scores were evaluated for fluorescence in situ hybridization
(FISH), and a ratio of >2.2 of HER2 gene to chromosome
17 was considered positive for HER2 gene overexpression;
ratio <1.8 was considered negative for HER2 amplification,
and cases with a ratio between 1.8 and 2.2 were classified
as equivocal for HER2 amplification [20]. The Ki-67
proliferation index was determined in the area with the
highest Ki-67 nuclear labeling. A total of 300 proliferating
and nonproliferating cells were counted, and the per-
centage of proliferating cells was calculated. Table 1
summarizes the specifications of the primary antibodies
used.
Molecular subtype classification
Immunohistochemical surrogate markers (ER, PR, HER2,
Ki-67, EGFR and CK5/6) were used to determine the mo-
lecular category of breast cancer as previously described
in the following groups: luminal A (ER + and/or PR+,
HER2- and Ki-67 < 14%), luminal B (ER + and/or PR+,
HER2- and Ki-67 > 14%), triple-positive (TP) (ER + and/or
PR+, HER2+), HER2-enriched (ER- and PR- and HER2+),
and triple-negative (TN) (ER-, PR- and HER2-) [21,22].
HER2+ included all the cases with a score of 3+ by
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immunohistochemistry and cases with score 2+ but
showing amplification demonstrated by FISH according
to the guidelines of The American Society of Clinical
Oncology (ASCO) and the College of American Pathologists
(CAP) [20].
Statistical analysis
Descriptive statistical analysis was used to characterize
the distribution of the patient’s age at diagnosis, hormo-
nal receptor status, HER2 status, and molecular subtypes
for the total sample and by the geographic region. Com-
parisons of the age of patients between different geo-
graphic regions, molecular subtypes, ER/PR status, and
HER2 status were performed using the Kruskal-Wallis
test. Associations between molecular subtypes, hormonal
receptor status, HER2 expression, and categories of
patient’s age with geographic regions were tested by a
chi-square test. Missing values were not included in
our statistical analysis and were deleted list-wise. Statis-
tical analyses were performed using MedCalc for Win-
dows (version 11.5.0.0; MedCalc Software, Mariakerke,
Belgium), and a p-value less than 0.05 was considered
significant.
Institutional approval
The study was approved by the Scientific Committee of
the Department of Pathology of the Faculdade de Medicina
da Universidade de Sao Paulo, and also by the Ethical
Committee for Research Projects of the Hospital das
Clinicas da Faculdade de Medicina da Universidade de
Sao Paulo (CAPPesq) (protocol 311/10).
STROBE statement
This study has adhered to the STROBE guidelines for
observational studies.
Results
In total, 5,687 eligible cases were included in the final
analysis. The age of patients ranged from 16 to 98 years
(mean 55.5 ± 13.5 years, median = 54 years). The distri-
bution of age at diagnosis, hormonal and HER2 status,
and the molecular subtypes are summarized in Table 2.
In regional distribution, the age at diagnosis had the
lowest mean in the North and Central-West regions and
among patients with negative ER/PR, and HER2- posi-
tive tumors (Tables 2 and 3). Among molecular subtypes,
however, the lowest mean age was seen among patients
Table 1 Source and dilutions of the antibodies and epitope retrieval methods used in this study
Antibody to Clone Source Dilution Epitope retrieval
Estrogen receptor Rabbit monoclonal antibody, SP1 Thermo Scientific 1:500 Pressure cooker, 9 min
Progesterone receptor Mouse monoclonal antibody, PgR636 Dako 1:1000 Pressure cooker, 9 min
HER2 Rabbit monoclonal antibody, SP3 Thermo Scientific 1:100 Microwave oven
Ki-67 Mouse monoclonal antibody, MIB1 Dako 1:600 Pressure cooker, 9 min
HER2: human epidermal growth factor receptor 2; Pressure cooker: citrate buffer (pH 6) (Tender Cooker, Nordic Wave, USA). Microwave: citrate buffer (pH 6),
15 min (Electrolux®, 900 W).
Table 2 Comparison of age of patients at breast cancer diagnosis, molecular subtype, expression of estrogen and
progesterone receptor, and HER2 status among the five Brazilian geographic regions
Variable Brazilian geographic regions p-value
SE S NE CW N
Age (mean ± SD) 56.1 ± 13.5 55.8 ± 13.9 55.3 ± 13.7 54.3 ± 12.8 53.9 ± 13.1 <0.0001a
Molecular subtype Luminal A 707 (28.8%) 324 (30.8%) 226 (24.1%) 143 (25.9%) 171 (25.3%) <0.0001b
Luminal B 971 (39.5%) 388 (36.9%) 348 (37.1%) 190 (34.6%) 208 (30.8%)
Triple-positive 238 (9.7%) 114 (10.8%) 100 (10.7%) 71 (12.9%) 68 (10.1%)
HER2 195 (7.9%) 71 (6.7%) 99 (10.5%) 49 (8.9%) 91 (13.5%)
Triple-negative 345 (14.0%) 154 (14.6%) 163 (17.4%) 96 (17.4%) 137 (20.3%)
Non-availablec 4 5 3 2 3
ER/PR Positive 2039 (82.8%) 871 (82.5%) 753 (80.0%) 418 (75.9%) 529 (78.0%) 0.0003b
Negative 422 (17.1%) 185 (17.5%) 188 (20.0%) 133 (24.1%) 149 (22.0%)
HER2 Positive 433 (17.6%) 188 (17.8%) 201 (21.3%) 119 (21.6%) 163 (24.0%) 0.017b
Negative 1972 (80.1%) 846 (80.1%) 725 (77.0%) 422 (76.6%) 506 (74.6%)
Score2+ 56 (2.3%) 22 (2.1%) 15 (1.6%) 11 (2.0%) 9 (1.3%)
Total 2461 1056 941 551 678
aKruskal-Wallis; bchi-square; cHER2 score 2+ and no FISH study to define the HER2 status.
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with a TP phenotype followed by TN carcinomas (Table 3).
The distribution of the molecular subtypes differed in the
five regions, which is illustrated in Figure 1. Luminal A
carcinomas were more frequent in the Southeast (28.8%)
and South (30.8%) regions. The highest proportion of
luminal B carcinomas (39.5%) was seen in the Southeast
region (p < 0.0001). Actually, the Southeast and South re-
gions presented the highest proportion of ER/PR-positive
tumors (p = 0.0003) (Table 2). HER2-enriched tumors
were most frequent in the North region. The highest pro-
portion of TP carcinomas came from the Central-West re-
gion. Triple negative carcinomas were more prevalent in
the North region (p < 0.0001) (Table 2). The differences of
frequency of the molecular subtypes in the five geographic
regions persisted when we analyzed the subgroups of
patients under 51 years (p = 0.0001) and over 50 years
(p = 0.0012) (Table 4).
Table 5 summarizes the distribution of our cases, the
official data of the Brazilian female population, and the
incidence of breast cancer in the five geographical re-
gions. Figure 1 illustrates the distribution of all the cases
in this study according to the geographical regions.
Discussion
Brazil is a large country with a surface area of 8,511,960 km2
and with a population of 190,755,799. It is the most
populous country in Latin America as well as one of
the most populous in the world. The female popula-
tion, according to the official 2010 census, is 97,348,809
[15]. We found significant differences in the proportion of
the molecular subtypes of breast cancer between the five
Brazilian geographic regions—each one with a distinct
racial composition together with differences in climate,
nutritional habits, urbanization and socioeconomic
conditions.
The Brazilian racial composition is very heterogeneous
with most populations descending from Europeans,
Africans, Amerindians of various ethnic groups, and
Asians. Most importantly, Brazil has experienced a
high rate of intermarriage, and consequently, a mixed-
race population has been created along five centuries
of admixture.
A racial/ethnic influence on the presentation of breast
cancer has been suggested in various studies [7,14,23-26]
although race definition was neither very clear nor uni-
form in these studies. Most investigated race as a social
characteristic without biologic basis of classification.
Carey et al. conducted a population-based, case-controlled
study with cases from the Carolina Breast Cancer Study
and observed a higher prevalence of basal-like among
premenopausal African Americans (39%) compared with
postmenopausal African Americans (14%) and non-African
American patients of any age (16%) [7]. Kurian et al. dem-
onstrated different lifetime risks of the distinct subtypes
defined by the ER, PR, and HER2 status among black,
Hispanic, Asian, and white women [26]. The authors found
a higher lifetime risk of TN tumors in black women and
discussed the importance of this data on health policy and
resource planning.
The high prevalence of basal-like tumors in premeno-
pausal African Americans is pointed to as an important
factor to the poorer prognosis in this group of patients
[27,28], justifying the higher mortality rate despite the
lower incidence [13,14]. Harper et al. documented 31/
100,000 annual deaths among African Americans com-
pared with 27/100,000 annual deaths for white women
[29]. Delay in diagnosis due to disparities in healthcare
Table 3 Comparison of age among different geographic regions, molecular subtypes, ER/PR status, and HER2 status
Factor n Mean ± SD (years) Significant difference (<0.05) from other factor(s)a
Geographic Region (1) CW 551 54.3 (5)
(2) N 678 53.9 (3)(4)(5)
(3) NE 941 55.3 (2)
(4) S 1056 55.8 (2)
(5) SE 2461 56.1 (1)(2)
Molecular subtype (1) HER2 505 54.2 ± 12.8 (2)(5)
(2) LUM A 1571 58.5 ± 13.0 (1)(3)(4)(5)
(3) LUM B 2104 55.7 ± 13.7 (2)(4)(5)
(4) TN 894 53.1 ± 13.4 (2)(3)(5)
(5) TP 591 51.6 ± 13.0 (1)(2)(3)(4)
ER/PR status (1) Positive 4610 55.6 ± 13.5 (2)
(2) Negative 1077 53.4 ± 13.4 (1)
HER2 status (1) Positive 1104 52.8 ± 12.9 (2)
(2) Negative 4470 56.1 ± 13.6 (1)
aKruskal-Wallis test, p < 0.0001 for all variables.
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Figure 1 Brazilian map with the 5 geographic regions showing the distribution of 5,687 cases of breast cancer according to molecular
subtypes determined by immunohistochemical surrogates.
Table 4 Comparison of the molecular subtypes among the five Brazilian geographic regions according to age of
patients at diagnosis
Geographic
regions
Molecular subtypes
Luminal A Luminal B Triple-positive HER2 Triple-negative
Age at
diagnosis
<50y ≥50y <50y ≥50y <50y ≥50y <50y ≥50y <50y ≥50y
Southeast 188/810
(23.2%)
519/1651
(31.4%)
332/810
(41.0%)
639/1651
(38.7%)
94 /810
(11.6%)
144/1651
(8.7%)
60/810
(7.4%)
135/1651
(8.2%)
135/810
(16.7%)
210/1651
(12.7%)
South 91/387
(23.5%)
233/669
(34.8%)
150/387
(38.7%)
238 /669
(35.6%)
57/387
(14.7%)
57/669
(8.5%)
25/387
(6.5%)
46/669
(6.9%)
63/387
(16.3%)
91/669
(13.6%)
Northeast 58/348
(16.7%)
168/592
(28.4%)
130/348
(37.3%)
217/592
(36.7%)
58/348
(16.7%)
42/592
(7.1%)
37/348
(10.6%)
62/592
(10.5%)
64/348
(18.4%)
99/592
(16.7%)
Central
West
43/218
(19.7%)
100/332
(30.1%)
80/218
(36.7%)
110/332
(33.1%)
37/218
(17.0%)
34/332
(10.2%)
19/218
(8.7%)
30/332
(9.0%)
39/218
(17.9%)
56/332
(16.9%)
North 36/262
(13.7%)
135/415
(32.5%)
90 /262
(34.3%)
118/415
(28.4%)
28/262
(10.7%)
40/415
(9.6%)
35/262
(13.4%)
56/415
(13.5%)
72/262
(27.5%)
65/415
(15.6%)
Chi square test, patients <50y, p = 0.0001; Chi-square test, patients ≥50y, p = 0.001.
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access may contribute to higher rates of late-stage
presentation and partially explain the increased rate of
annual death in African Americans. In this study, we
did not evaluate the stage or prognostic or outcome—
factors influenced by social-economic status—but only
the molecular subtype as a variable in geophysical dis-
tribution. In Brazil, besides the complexity of racial
composition, the five geographic regions differ from each
other regarding climate, urbanization, socioeconomic sta-
tus, and nutritional habits— conditions that potentially
can interfere in carcinogenesis as well as in the diagnosis
and outcome of breast cancer.
In our study, Northern Brazil presented the highest pro-
portion of TN carcinomas (20.3%). This region, largely
covered by the Amazon rainforest, presents the largest
Amerindian influences, both in culture and ethnicity.
Indians represent 0.4% of the total Brazilian population
[19], but they make up 1.5% of the Northern region.
This region also has the highest African influence
(77.8%), compared to 66.8% in Northeast, 65.9% in
Central-West, 43.8% in Southeast, and 22.8% in South [15].
We must consider, however, the difficulty in defining
race in Brazil and the need of a genomic classification.
Pena et al. estimated the proportion of European, African,
and Amerindian ancestry using a panel of 40 validated
ancestry-informative insertion-deletion DNA polymor-
phisms in a population composed by black, white, and
brown people from the four most populous Brazilian
geographic regions (North, South, Northeast and South)
[18]. The results were surprising as the authors were
unable to demonstrate statistically significant differences
among the four studied regions [18]. The authors found
that European ancestry was predominant in all regions,
varying from 60.6% in the Northeast to 77.7% in the
South. Besides the difficulty to determine race in Brazil,
these data show an important difference between the so-
cial and genomic determination of the African influence,
particularly among the North population. The large area
of Brazil has a variety of climate zones: equatorial, tropical,
semi-arid, highland tropical and subtropical, each one
with different life style, in part determined by the contri-
bution of different ethnical groups, part by the substantial
differences in the industrialization degree and social
development.
The South region of Brazil houses the largest percent-
age of European descents, including German, Italian and
Polish ancestry. White races comprise 80.6% of the
population in this region compared to 24% in the North,
29.5% in the Northeast, 58.5% in the Southeast and
43.5% in the Central-West. According to our results, the
South region showed the highest frequency of luminal A
carcinomas—the more favorable molecular subtype—as
well as a higher frequency of ER/PR-positive tumors,
which is consistent with other studies [7,30,31]. Accord-
ing to the Brazilian National Institute of Cancer (INCA),
Rio Grande do Sul, a state in the Southern region with a
great influence of Italians and Germans boasts the highest
incidence of breast cancer with 71 cases/100,000 women
[19], which is consistent with other studies [14]. Our re-
sults indicated that most of our breast cancers located in
this geographic region are a luminal A subtype and simul-
taneously presented with the lowest rate of HER2, TP, and
TN tumors, suggesting an overall better prognosis.
The second region with a high proportion of luminal
A and ER/PR-positive carcinomas was the Southeast,
which was also the region with the second largest white
population. The lowest incidence of luminal A was doc-
umented in the North, which presented a rate of breast
cancer varying from 10 cases/100,000 women in the state
of Acre to 26 cases/100,000 women in the state of
Rondonia [19]. According to INCA, the only state of
the North with a discrepant higher rate of breast cancer
is Tocantins, which is located near the Central-West
region, with 27 cases/100,000 women [19].
In addition to luminal A carcinomas, the luminal B cat-
egory also was more prevalent in the South and Southeast
and showed a lower frequency in the North region. It is
important to stress that our luminal B did not include
HER2-coexpression, like some authors have classified
[7,11]. We analyzed the TP phenotype separately using
classification criteria suggested by the previous St. Gallen
consensus [32]. The TP phenotype was more frequent in
the Central-West region, while HER2-enriched carcinomas
were more prevalent in the North. In fact, our results
Table 5 Distribution of 5,687 cases compared to overall and female Brazilian population among the five geographic
regions, and incidence of breast cancer/100,000 women among females
Geographic Regions Total populationa Total female populationa Incidence of breast cancer/100,000b Our cases
North 15,864,454 (8%) 7,859,539 (8.1%) 21 678 (12%)
Northeast 53,081,950 (27%) 27,172,904 (27.9%) 37 941 (16%)
Southeast 80,364,410 (42%) 41,287,763 (42.4%) 71 2,461 (43%)
South 27,386,891 (14%) 13,950,480 (14.3%) 71 1,056 (18.6%)
Central West 14,058,094 (7%) 7,078,123 (7.2%) 51 551 (9%)
Total 190,755,799 97,348,809 56 5,687
aData from Census 2010 IBGE [15]; bData from Brazilian National Cancer Institute (INCA) [19].
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indicated that more aggressive molecular subtypes are
more prevalent in the North. This information must be
considered in the planning of breast cancer prevention
programs.
The distribution of HER2 carcinomas among different
races/ethnic groups is more difficult to analyze because
some authors included TP within the HER2 group [26],
and others, within luminal B [7,11,13,30]. Fewer studies
analyzed the group separately as we did. Kurian et al.
did not find differences in the distribution of HER2-
carcinomas, but they included TP among their HER2
tumors [26].
The differences in molecular subtypes that we ob-
served among the five geographic regions persisted in
the subgroups of patients under and over 50 years, sug-
gesting the existence of a geographic phenomenon more
than effect of age itself. Similar results have been reported
by others [30]. Clarke et al. analyzed the distribution of
the breast cancer subtypes among 91,908 patients from
California and observed that black-women had higher
rates of triple-negative carcinomas at all ages. The North
region presented the lowest mean of age, and it was statis-
tically different when compared to the Northeast, South,
and Southeast.
Although we found significant differences in the distri-
bution of molecular subtypes between the five geographic
regions, we could not associate them to African ancestry,
as other studies have been able to do in primarily the
USA, despite the important African influence in the
Brazilian racial composition. The reasons for this find-
ing remain to be explored. One possible explanation is
that the influence of African ancestry in Brazil may be
different from that seen in the USA and Europe due to
high rate of interracial marriage seen in Brazil. How-
ever, as we discussed above, there are other important
factor to be considered,
There are studies that explored some genetic condi-
tions implicated with racial/ethnic differences in breast
cancer. Wang et al. observed a significantly higher
methylation of the suppressor gene CDH13 in breast tumor
samples from African-American women when compared
with European-American patients. The hypermethylation of
the CDH13 gene probably is related to early onset ER-
negative breast cancer [33]. Several single-nucleotide
polymorphisms (SNPs) have been associated to age and
race of breast cancer patients [34]. Associations were
observed for SNPs in FGFR2, LSP1, H19, TLR1/TLR6
and RELN for African-Americans and in FGFR2, TNRC9,
H19 and MAP3K1 for whites [34]. It is highly probable
that the racial admixture can be responsible for some
genomic differences, which are not necessarily similar
to the ancestry.
Health disparities, either by racial/ethnic, socioeconomic,
cultural, climatic, nutritional, or geographic are very
complex to decode since there is a significant overlap
between these factors [35]. Understanding the differences
in breast cancer characteristics between geographic re-
gions is the first step to organize healthcare programs.
Moreover, this knowledge has important impact for the
design and interpretation of clinical trials. As such, we be-
lieve that our study is relevant to determining the best
strategy of health care and to better understand the tumor
biology of breast cancer in large countries like Brazil with
diverse economic and race composition among different
geographic regions.
Conclusions
The distribution of molecular subtypes of breast cancer
differs by geographic region in Brazil, a country of
continental dimension and a wide racial variation of
people. These differences are multifactorial and must
be taken into account for public health policy.
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